$830 Million is the total value of Atlas Venture Life Science Advisors, LLC's 17 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 11.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DAWN | Sell | Day One Biopharmaceuticals, Inc. | $162,870,182 | -0.5% | 7,568,317 | -7.4% | 19.62% | +8.6% |
| KYMR | Sell | Kymera Therapeutics, Inc. | $149,379,011 | -0.2% | 5,984,736 | -13.0% | 17.99% | +8.9% |
| DYN | Buy | Dyne Therapeutics, Inc. | $114,387,308 | +0.8% | 9,869,483 | +10.5% | 13.78% | +10.0% |
| Vigil Neuroscience, Inc. | $72,960,925 | +37.4% | 5,836,874 | 0.0% | 8.79% | +49.9% | ||
| New | Disc Medicine, Inc. | $68,854,884 | – | 3,461,784 | +100.0% | 8.29% | – | |
| AVTE | Sell | Aerovate Therapeutics, Inc. | $59,113,365 | +53.2% | 2,017,521 | -13.3% | 7.12% | +67.2% |
| REPL | Sell | Replimune Group, Inc. | $57,073,760 | +6.3% | 2,098,300 | -32.5% | 6.88% | +16.1% |
| Third Harmonic Bio, Inc. | $46,903,794 | -77.3% | 10,907,859 | 0.0% | 5.65% | -75.3% | ||
| AKRO | Sell | Akero Therapeutics, Inc. | $32,564,955 | -3.8% | 594,251 | -40.2% | 3.92% | +5.0% |
| GBIO | Generation Bio, Co. | $32,535,983 | -26.0% | 8,278,876 | 0.0% | 3.92% | -19.2% | |
| IKNA | Ikena Oncology, Inc. | $13,348,353 | -25.1% | 5,018,178 | 0.0% | 1.61% | -18.2% | |
| Xilio Therapeutics, Inc. | $7,422,635 | -7.6% | 2,759,344 | 0.0% | 0.89% | +0.9% | ||
| FSTX | F-star Therapeutics, Inc. | $3,788,992 | +23.4% | 599,524 | 0.0% | 0.46% | +34.5% | |
| AVRO | AVROBIO INC | $3,222,923 | +10.9% | 4,520,863 | 0.0% | 0.39% | +20.9% | |
| VRDN | Viridian Therapeutics, Inc. | $2,631,003 | +42.4% | 90,072 | 0.0% | 0.32% | +55.4% | |
| SPRO | SPERO THERAPEUTICS INC | $1,783,907 | -13.5% | 1,031,160 | 0.0% | 0.22% | -5.7% | |
| MGTA | MAGENTA THERAPEUTICS INC | $1,373,232 | -72.0% | 3,476,536 | 0.0% | 0.16% | -69.5% | |
| GMTX | Exit | Gemini Therapeutics, Inc. | $0 | – | -5,254,365 | -100.0% | -0.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.